Atorvastatin vs Rosuvastatin: side-by-side comparison
Atorvastatin and Rosuvastatin belong to the same class (HMG-CoA reductase inhibitor (statin)). They share therapeutic approach but differ in mechanism nuances, half-life, side-effect profile and available formulations. This comparison summarises what is common and where they diverge.
| Property | Atorvastatin | Rosuvastatin |
|---|---|---|
| Therapeutic class | HMG-CoA reductase inhibitor (statin) | HMG-CoA reductase inhibitor (statin) |
| CAS | 134523-00-5 | 287714-41-4 |
| ATC | C10AA05 | C10AA07 |
| Molecular weight | 558.65 g/mol | 481.54 g/mol |
| Brands with this active ingredient | 1 | 1 |
What they share
Both are in the HMG-CoA reductase inhibitor (statin) class, giving them a common pharmacological architecture and many shared safety and management points. Choice within the class comes down to mechanism nuances, half-life, side-effect profile and individual response.
Key differences
Differences within the HMG-CoA reductase inhibitor (statin) class are what matter in practice: half-life, route of administration, equivalent doses, specific interactions, predominant side-effect profile and accumulated clinical experience. This page frames them; the prescribing information gives quantitative detail.
Mechanisms compared
Atorvastatin: Atorvastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. Rosuvastatin: Rosuvastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis.
Indications compared
Atorvastatin: Atorvastatin is approved in adults for the treatment of primary hypercholesterolaemia and mixed dyslipidaemia, for the prevention of cardiovascular events in patients at elevated risk and for the secondary prevention of… Rosuvastatin: Rosuvastatin is approved in adults for the treatment of primary hypercholesterolaemia and mixed dyslipidaemia, for the prevention of cardiovascular events in patients at elevated risk and for the secondary prevention of…
Safety profile
Atorvastatin: The most common adverse effects include myalgia, gastrointestinal symptoms and mild elevations of liver enzymes. Rosuvastatin: Common adverse effects include myalgia, gastrointestinal symptoms, headache and mild elevations of liver enzymes.
Frequently asked questions
Is Atorvastatin better than Rosuvastatin? ▾
Neither is universally better. Atorvastatin and Rosuvastatin share the HMG-CoA reductase inhibitor (statin) class but differ in half-life, mechanism nuances and side-effect profile. The choice depends on the patient and the prescriber.
Can Atorvastatin and Rosuvastatin be combined? ▾
Combining two ingredients from the same HMG-CoA reductase inhibitor (statin) class is uncommon and, in most cases, adds no benefit over one at an appropriate dose. The decision is always the prescriber's.
Do they have the same side-effect profile? ▾
Partly yes — they share many HMG-CoA reductase inhibitor (statin) class effects, with nuances by mechanism and dose. The prescribing information lists differences.
Products with Atorvastatin
Products with Rosuvastatin
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.